Purine Analogs in Leukemia

Advances in Pharmacology

Volumn 51, Issue , 2004, Pages 107-125

  Lamanna, Nicole ^a   Weiss, Mark ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; DRUG DERIVATIVE; FLUDARABINE; PENTOSTATIN; PURINE; PURINE DERIVATIVE; VIDARABINE;

HUMAN; LEUKEMIA; METABOLISM; PATHOLOGY; REVIEW; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CLADRIBINE; HUMANS; LEUKEMIA; PENTOSTATIN; PURINES; STEM CELL TRANSPLANTATION; VIDARABINE;

EID: 16544379451     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(04)51005-0     Document Type: Article

References (95)

1. J.C. Adkins D.H. Peters A. Markhan Fludarabine: An update of its pharmacology and use in the treatment of hematological malignancies Drugs 53 1997 1005 1037
2. E. Anaissie D.P. Kontoyiannis H. Kantarjian L. Elting L.E. Robertson M. Keating Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone Ann. Intern. Med 117 1992 466 469
3. M. Bornhauser C. Thiede U. Schuler U. Platzbecker J. Freiberg-Richter A. Helwig R. Plettig C. Rollig R. Naumann F. Kroschinsky A. Neubauer G. Ehninger Dose reduced conditioning for allogenic blood stem cell transplantation: Durable engraftment without antithymocyte globulin Bone Marrow Transplant 26 2001 119 125
4. H.M. Bryson E.M. Sorkin Cladribine. A review of its phmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies Drugs 46 1993 872 894
5. J.C. Byrd B.L. Peterson V.A. Morrison K. Park R. Jacobson E. Hobe J.W. Vardiman K. Rai C.A. Schiffer R.A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood 101 2003 6 14
6. D.A. Carson B. Wassun R. Taetle A. Yu Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes Blood 62 1983 737 743
7. G.W. Chan F.M. Foss T. Roberts K. Spraque D. Schenkein K.B. Miller Age is not associated with adverse outcomes following pentostatin-based preparative regimen for allogeneic bone marrow transplant [Abstract] Blood 98 2001 313b
8. A. Cohen J.W. Lee E.W. Gelfand Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells Blood 61 1983 660 666
9. J. Cortes H. Kantarjian M. Talpaz S. O'Brien M. Beran C. Koller M. Keating Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine Leukemia 11 1997 788 791
10. M.S. Czuczman A. Fallon A. Mohr C. Stewart Z.P. Bernstein I. McCarthy M. Skipper K. Brown K. Miller D. Wentling D. Klippenstein P. Loud M.K. Rock M. Benyunes A.J. Grillo-Lopez S.H. Bernstein Rituximab in combination with CHOP or fludarabine in low-grade lymphoma Semin. Oncol 29 2002 36 40
11. F.J. Dann J. Anastasi A. Larson High dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase J. Clin. Oncol 16 1998 1498 1504
12. L. Elias D. Stock-Novack D.R. Head M.R. Grever J.K. Weick R.A. Chapman J.E. Godwin E.N. Metz E.R. Appelbaum A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study Leukemia 3 1993 361 365
13. E. Estey W. Plunkett V. Gandhi M.B. Rios H. Kantarjian M.J. Keating Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia Leuk. Lymph 9 1993 343 350
14. E.H. Estey P.F. Thall J.E. Cortes F.J. Giles S. O'Brien S.A. Pierce X. Wang H.M. Kantarjian M. Beran Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts Blood 98 2001 3575 3583
15. I.W. Flinn J. Byrd C. Morrison J. Jamison L.F. Diehl T. Murphy S. Piantadosi E. Seifter R.F. Ambinder G. Vogelsang M.R. Grever Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 2000 71 75
16. I.W. Flinn K.J. Kopecky M.K. Foucar D. Head J.M. Bennett R. Hutchison W. Corbett P. Cassileth T. Habermann H. Golomb K. Rai E. Eisenhauer F. Appelbaum B. Cheson M.R. Grever Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin Blood 96 2000 2981 2986
17. V. Gandhi Fludarabine for treatment of adult acute myelogenous leukemia Leuk. Lymph 11 Suppl. 2 1993 13
18. V. Gandhi E. Estey M.J. Keating A. Chucrallah W. Plunkett Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions Blood 87 1996 256 264
19. V. Gandhi E. Estey M.J. Keating W. Plunkett Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J. Clin. Oncol 11 1993 116 124
20. V. Gandhi W. Plunkett Cellular and clinical pharmacology of fludarabine Clin. Pharm 41 2002 93 103
21. V. Gandhi W. Plunkett S. Weller M. Du M. Ayres C.O. Rodriguez Jr. P. Ramakrishna G.L. Rosner J.P. Hodge S. O'Brien M.J. Keating Evaluation of the combination of nelzarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells J. Clin. Oncol 19 2001 2142 2152
22. D. Genini S. Adachi O. Chao D.W. Rose C.J. Carrera H.B. Cottam D.A. Carson L.M. Leoni Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly effecting the mitochondria Blood 96 2000 3537 3543
23. S. Giralt E. Estey M. Albitar K. van Besien G. Rondon P. Anderlini S. O'Brien I. Khouri J. Gajewski R. Mehra D. Claxton B. Andersson M. Beran D. Przepiorka C. Koller S. Kornblau M. Korbling M. Keating H. Kantarjian R. Camplin Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531 4536
24. S. Giralt P. Thall S. Khouri X. Wang I. Braunschweig C. Ippolitti D. Claxton M. Donato J. Bruton A. Cohen M. Davis B.S. Andersson P. Anderlini J. Gajewski S. Kornblau M. Andreeff D. Przepiorka N.T. Ueno J. Molldrem R. Champlin Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogenic progenitor cell transplantation Blood 97 2001 631 637
25. M.S. Gordon M.L. Young M.D. Tallman L.D. Cripe J.M. Bennett E. Paietta W. Longo H. Gerad J. Mazza J.M. Rowe Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed⧸refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995 Leuk. Res 24 2000 871 875
26. M.R. Grever K.J. Kopecky C.A. Coltman J.C. Files B.R. Greenberg J.J. Hutton R. Talley D.D. Von Hoff S.P. Balcerzak Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia Nouv. Rev. Fr. Hematol 30 1988 457 459
27. M. Grever K. Kopecky M.K. Foucar D. Head J.M. Bennett R.E. Hutchinson W.E. Corbett P.A. Cassileth T. Habermann H. Golomb Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study J. Clin. Oncol 13 1995 974 982
28. M.R. Grever J.M. Leiby E.H. Kraut H.E. Wilson J.A. Neidhart R.L. Wall S.P. Balcerzak Low-dose deoxycoformycin in lymphoid malignancy J. Clin. Oncol 3 1985 1196 1201
29. M.R. Grever M.F.E. Siaw W.F. Jacob J.A. Neidhart J.S. Miser M.S. Coleman J.J. Hutton S.P. Balcerzak The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoid malignancy Blood 57 1981 406 417
30. J. Griffig R. Koob R.L. Blakley Mechanisms of inhibition of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells Cancer Res 42 1989 6923 6928
31. J. Gutheil C. Kearns Antimetabolites M. Perry “The Chemotherapy Source Book” 1997 Williams & Wilkins Baltimore, MD 330 336 chap 20,
32. M. Hallek B. Schmitt M. Wilhelm R. Busch A. Krober H.P. Fostitsch O. Sezer M. Herold W. Knauf C.M. Wendtner R. Kuse M. Freund A. Franke F. Schriever C. Nerl H. Dohner E. Thiel W. Hiddemann G. Brittinger B. Emmerich Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group Br. J. Haematol 114 2 2001 342 348
33. Y. Hirota A. Yoshioka S. Tanaka K. Watanabe T. Otani J. Minowada A. Matsuda T. Ueda Y. Wataya Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells Cancer Res 49 1989 915 919
34. M.A. Hoffman D. Janson E. Rose K.R. Rai Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up J. Clin. Oncol 15 1997 1138 1142
35. J. Holowiecki S. Grosicki T. Robak S. Krzemien A. Hellman A. Skotnicki W. Jedrzejczak K. Kluczkowski L. Konopka B. Zdziarska A. Pluta A. Dmoszynska S. Maj S. Giebel K. Zawilska M. Komarnicki J. Kloczko An original, multicenter randomized phase III trial comparing 2-CdA combined with cytarabine and daunorubicin (DAC-7) with standard cytarabine and daunorubicin (DA-7) for remission induction therapy in newly diagnosed, adult acute myeloid leukemia (Abstract) Blood 98 2001 592a
36. J. Holowiecki T. Robak S. Kyrcz-Krzemien S. Grosicki A. Hellmann A. Skotnicki Daunorubicin, cytarabine and 2-CdA (DAC-7) for remission induction in “ de novo ” adult acute myeloid leukemia patients Acta. Haematol. Polon 33 2002 839 847
37. P. Huang S. Chubb W. Plunkett Termination of DNA synthesis by 9-β- d -arabinosyl-2-fluoroadenine: A mechanism for cytotoxicity J. Biol. Chem 265 1990 16617 16625
38. H. Kantarjian V. Gandhi J. Cortes S. Verstovsek M. Du G. Garcia-Manero F. Giles S. Faderl S. O'Brien S. Jeha J. Davis Z. Shaked A. Craig M. Keating W. Plunkett E.J. Freireich Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia Blood 2003 First Edition Paper, prepublished online June 5, 2003; DOI 10.1182⧸blood-2003-03-0925.
39. H. Kantarjian V. Gandhi P. Kozuch S. Faderl F. Giles J. Cortes S. O'Brien N. Ibrahim F. Khuri M. Du M.B. Rios S. Jeha P. McLaughlin W. Plunkett M. Keating Phase I clinical and pharmacology study of clofarabine (CL-F-ara-A; 2-chloro-2′-fluoro-deoxy-9-β- d -arabinofuranosyladenine) in patients with solid and hematologic cancers J. Clin. Oncol 21 2003 1167 1173
40. M.J. Keating H. Kantarjian S. O'Brien C. Koller M. Talpaz J. Schachner C.C. Childs E.J. Freirich K.B. McCredie Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J. Clin. Oncol 9 1 1991 44 49
41. M.J. Keating H. Kantarjian M. Talpaz J. Redman C. Koller B. Barlogie W. Velasquez W. Plunkett E.J. Freirich K.B. McCredie Fludarabine: A new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
42. M.J. Keating S. O'Brien S. Lerner C. Koller M. Beran L.E. Robertson E.J. Freirich E. Estey H. Kantarjian Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 92 1988 1165 1171
43. I.F. Khouri M. Keating M. Korbling D. Przepiorka P. Anderlini S. O'Brien S. Giralt C. Ippoliti B. von Wolff J. Gajewski M. Donato D. Claxton N. Ueno B. Andersson A. Gee R. Champlin Transplant-like: Induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J. Clin. Oncol 16 1998 1958 1960
44. G. Konwalinka C. Helson S. Braverman G. Petzer R. Bilgeri U. Zihan Growth inhibitory properties of 2-chlorodeoxyadenosine (2-CdA): Growth inhibitory system tumors N.G. Abraham G. Konwalinka P. Marks Molecular biology of hematopoiesis 1992 Intercept Ltd Hanover, MA 603 613
45. S.M. Kornblau J. Cortes-Franco E. Estey Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia Leukemia 7 1993 378 383
46. S.M. Kornblau V. Gandhi H.M. Andreeff M. Beran H.M. Kantarjian C.A. Koller S. O'Brien W. Plunkett E. Estey Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults Leukemia 10 1996 1563 1569
47. T.A. Krenitsky G.W. Koszalka J.V. Tuttle J.L. Rideout G.B. Elion An enzymatic synthesis of purine- d -arabinonucleosides Carbohydr. Res 97 1981 129 146
48. D. Kufe D. Spriggs E.M. Egan D. Munroe Relationships among Ara-CTP pools, formation of (Ara-C) DNA, and cytotoxicity of human leukemic cells Blood 64 1984 54 58
49. J. Kurtzberg T.J. Ernst M.J. Keating V. Gandhi J.P. Hodge D.F. Kisor R. Therriault C. Stephens J. Levin T. Krenitsky G.B. Elion B.S. Mitchell A phase I study of 2-amino-9-β- d -arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies Blood 94 Suppl. 1999 2794a
50. N. Lamanna M.A. Weiss P.G. Maslak A.N. Gencarelli D.A. Scheinberg D. Horgan Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia Proc. ASCO 22 2003 580 (abstract 2333).
51. C.U. Lambe D.R. Averett M.T. Paff J.E. Reardon J.G. Wilson T.A. Krenitsky 2-amino-6-methoxypurine arabinoside: An agent for T-cell malignancies Cancer Res 55 1995 3352 3356
52. D. Liu K. Seiter J.W. Chiao J. Nelson R. Kancherla D. Siddiqui N. Cereb S. Yang T. Ahmed MAP regimen: A novel non-myeloablative conditioning regimen of mitoxantrone, Ara-C, and pentostatin (MAP regimen) for hematological malignancies [abstract] Blood 100 2002 622a
53. R.S. Marks L. Letendre J.M. Reid P.G. Bagniewski M.M. Ames A Phase I and pharmacologic study of chlorodeoxyadenosine in patients with chronic myelomonocytic or chronic granulocytic leukemia Proc. ASCO 13 1994 155 (abstract 415).
54. G. Martinelli N. Testoni E. Zuffa G. Visani P.L. Zinzani A. Zaccaria P. Farabegoli M. Arpinati M. Amabile S. Tura FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph + chronic myelogenous leukemia Leuk. Lymph 22 1996 173 176
55. M. Michallet K. Bilger F. Garban M. Attal A. Huyn D. Blaise N. Milpied P. Moreau P. Bordigoni M. Kuentz A. Sadoun J.Y. Cahn G. Socie X. Thomas P. Arnaud N. Raus V. Lheritier A. Pigneux J.M. Boiron Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome J. Clin. Oncol 19 2001 3340 3349
56. J.A. Montgomery K. Hewson Synthesis of potential anticancer agents. X. Fluroadenosine J. Am. Chem. Soc 79 1957 4559
57. M. Montillo A. Tedeschi S. O'Brien F. Di Raimondo S. Lerner A. Ferrajoli E. Morra M.J. Keating Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia Cancer 97 2003 114 120
58. S. O'Brien H.M. Kantarjian J. Cortes M. Beran C.A. Koller F.J. Giles S. Lerner M. Keating Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J. Clin. Oncol 19 5 2001 1414 1420
59. W.B. Parker S.C. Shaddix C.H. Chang E.L. White L.M. Rose R.W. Brockman A.T. Shortnacy J.A. Montgomery J.A. Secrist 3rd L.L. Bennett Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β- d -arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate Cancer Res 51 2001 2386 2394
60. S.Z. Pavletic G. Bociek J. Foran L. Hatcher R. Rubocki L. Kuszynsky D. Lucas M. Grever L. Hock S. Joshi P. Hardiman P. Bierman J. Vose J. Armitage J. Talmadge Immunological effects of pentostatin in a minimally myelosuppressive regimen for allogeneic stem cell transplantation [Abstract] Blood 100 2002 626a
61. L.D. Piro C.J. Carrera D.A. Carson E. Beutler Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine N. Engl. J. Med 322 1990 1117 1121
62. W. Plunkett V. Gandhi Purine and pyrimidine nucleoside analogs G. Giaccone R. Schilsky P. Sondel “Cancer Chemotherapy and Biological Response Modifiers, Annual 19” 2001 Elsevier Amsterdam 21 45
63. W. Plunkett P. Huang V. Gandhi Metabolism and action of fludarabine phosphate Sem. Oncol 17 Suppl. 8 1990 3 17
64. K.R. Rai B.L. Peterson F.R. Appelbaum J. Kolitz L. Elias L. Shepherd J. Hines G.A. Threatte R.A. Larson B.D. Cheson C.A. Schiffer Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N. Engl. J. Med 343 24 2000 1750 1757
65. K.R. Rai B. Peterson L. Elias L. Shepherd J. Hines D. Nelson B. Cheson J. Kolitz C.A. Schiffer A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG⧸NCI-I and ECOG Intergroup study [abstract] Blood 88 1996 552
66. E.J. Reist L. Goodman Synthesis of 9-β- d -arabinofuranosylguanine Biochemistry 3 1964 15 18
67. T. Robak J.Z Blonski M. Kasznicki M. Blasinska-Morawiec E. Krykowski A. Dmoszynska H. Mrugala-Spiewak A.B. Skotnicki W. Nowak L. Konopka B. Ceglarek S. Maj J. Dwilewica-Trojaczek A. Hellmann I. Urasinski B. Zdziarska S. Kotlarek-Haus S. Potoczek P. Grieb Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial Blood 96 2000 2723 2729
68. I.E. Robertson S. Chubb R.E. Meyn M. Story R. Ford W.N. Hittelman W. Plunkett Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β- d -arabinosyl-2-fluoroadenine Blood 81 1993 143 150
69. L.E. Robertson Y.O. Huh J.J. Butler N.C. Pugh C. Hirsch-Ginsberg S. Stass H. Kantarjian M.J. Keating Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic and molecular analysis Blood 80 1992 29 36
70. S. Sacchi H.M. Kantarjian S. O'Brien J. Cortes M.B. Rios F.J. Giles M. Beran C.A. Koller M.J. Keating M. Talpaz Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients Cancer 86 1999 2632 2641
71. T. Saito Y. Kanda M. Kami K. Kato N. Shoji S. Kanai T. Ohnishi Y. Kawano K. Nakai T. Ogasawara H. Matsubara A. Makimoto R. Tanosaki K. Tobinai H. Wakasugi Y. Takaue S. Mineishi Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan and antithymocyte globulin against advanced⧸refractory acute leukemia⧸lymphoma Clin. Cancer Res 8 2002 1014 1020
72. V.M. Santana C.A. Hurwitz R.L. Blakley W.R. Crom X. Luo W.M. Roberts R. Ribeiro H. Mahmoud R.A. Krance Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia Blood 84 1994 1237 1242
73. V.M. Santana J. Mirro Jr. F.C. Harwood J. Cherrie M. Schell D. Kalwinsky R.L. Blakley A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia J. Clin. Oncol 9 1991 416 422
74. V.M. Santana J. Mirro Jr. C. Kearns M.J. Schell W. Crom R.L. Blakley 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia J. Clin. Oncol 10 1992 364 370
75. A. Saven C. Burian J.A. Koziol L.D. Piro Long-term follow-up of patients with hairy cell leukemia after cladribine treatment Blood 92 1998 1918 1926
76. A. Saven L.D. Piro R.H. Lemon M.L. Figueroa M. Kosty D.J. Ellison E. Beutler Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine Cancer 73 1994 2953 2963
77. R.F. Schlenk F. Hartmann M. Hensel W. Jung R. Weber-Nordt A. Gabler R. Haas A.D. Ho L. Trumper H. Dohner Less intense conditioning with fludarabine, cyclophosphamide, idarubicin, and etoposide (FICE) followed by allogenic unselected peripheral blood stem cell transplantation in elderly patients with leukemia Leukemia 16 2002 581 586
78. S. Seto C.I. Carrera M. Kubota D.B. Wasson D.A. Carson Mechanism of deoxyadenosine and 2′-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes J. Clin. Invest 75 1985 377 383
79. J.F. Seymour P. Huang W. Plunkett V. Gandhi Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications of a continuous infusion schedule Clin. Cancer Res 2 1996 653 658
80. J.F. Seymour R. Kurzrock E.L. Freirich E.H. Estey 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia Blood 83 1994 2906 2911
81. M.F. Siaw M.S. Coleman In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA J. Biol. Chem 259 1984 9426 9433
82. S. Slavin A. Nagler E. Naparstek Y. Kapelushnik M. Aker G. Cividalli G. Varadi M. Kirschbaum A. Ackerstein S. Samuel A. Amar C. Brautbar O. Ben-Tal A. Eldor R. Or Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease Blood 91 1998 756 763
83. D.R. Spriggs E. Stopa R.J. Mayer W. Schoene D.W. Kufe Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study Cancer Res 46 1986 5953 5958
84. M.S. Tallman D. Hakimian A.W. Rademaker C. Zanzig E. Wollins E. Rose L.C. Peterson Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience Blood 88 1996 1954 1959
85. A. Tedeschi M. Montillo F. Ferrara A. Nosari G. Mele C. Copia P. Leoni E. Morra Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG) Eur. J. Haematol 64 2000 182 187
86. L. Vahdat E. Wong M. Wile M. Rosenblum K.M. Foley R.P. Warell Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia Blood 84 1994 3429 3434
87. E. Van Den Neste P. Martiat P. Mineur A. Delannoy C. Doyen A. Zenebergh J.L. Michaux A. Ferrant A. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia Ann. Hematol 76 1998 19 23
88. R.P. Warrell Jr. E. Berman Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity J. Clin. Oncol 4 1986 74 79
89. R. Wasch I. Reisser J. Hahn H. Bertz M. Engelhardt R. Kunzmann H. Veelken E. Holler J. Finke Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation Bone Marrow Transplant 26 2002 243 250
90. M.A. Weiss M. Glenn P. Maslak Z. Rahman A. Noy A. Zelenetz D.A. Scheinberg D.W. Golde Consolidation therapy with high-dose cyclophosphamide improves quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 14 2000 1577 1582
91. M.A. Weiss N. Lamanna P.G. Maslak A.N. Gencarelli D.A. Scheinberg J. Jurcic D. Horgan Pentostatin, cyclophosphamide and rituximab (PCR therapy): A new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL) Proc. ASCO 22 2003 580 (abstract 2334).
92. M.A. Weiss P.G. Maslak J.G. Jurcic D.A. Scheinberg T.B. Aliff N. Lamanna S.R. Frankel S.E. Kossman D. Horgan Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia J. Clin. Oncol 21 7 2003 1278 1284
93. M. Weiss T. Spiess E. Berman S. Kempin Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia Leukemia 8 1994 1290 1293
94. K.C. Xie W. Plunkett Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-B- d -arabinofuranosyl) adenine Cancer Res 56 1996 3030 3037
95. P.L. Zinzani M. Buzzi P. Farabegoli G. Martinelli P. Tosi E. Zuffa G. Visani N. Testoni M. Salvucci M. Bendandi Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells Haemtaolog 79 1994 127 131